Engineered immune cells aim to stop lymphoma in its tracks
NCT ID NCT07587840
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests a new approach using a patient's own immune cells, modified to target two markers (CD19 and CD22) on lymphoma cells, as a first-line consolidation treatment. It is for people with follicular lymphoma who had only a partial response to initial chemotherapy. The goal is to see if this therapy can improve the chance of staying cancer-free for at least one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.